NATCO Gains U.S. Approval For Generic Everolimus TFOS

NATCO Pharma Limited received approval for its ANDA of Everolimus tablets for oral suspension (TFOS) in three strengths: 2mg, 3mg, and 5mg as the generic version of AFINITOR DISPERZ® produced by Novartis Pharmaceutical Corporation. Breckenridge Pharmaceutical Inc. plans the market entry of the product as NATCO Pharma's marketing partner for the ANDA.

The kinase inhibitor Everolimus TFOS is used to treat subependymal giant cell astrocytoma (SEGA), which requires therapeutic intervention yet cannot be completely removed with surgery in adult and pediatric patients who are at least one year old with tuberous sclerosis complex (TSC). The U.S. market revenue for Everolimus tablets for oral suspension amounts to USD 112 million for 12 months through September 2024 as per observed industry figures.